Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2005-04-26
2005-04-26
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S171000, C514S174000, C514S178000, C514S311000, C514S654000, C424S489000, C424S493000
Reexamination Certificate
active
06884794
ABSTRACT:
The invention provides a formulation to be administered as dry powder for inhalation suitable for efficacious delivery of active ingredients into the low respiratory tract of patients suffering of pulmonary diseases such as asthma. In particular, the invention provides a formulation to be administered as dry powder for inhalation freely flowable, which can be produced in a simple way, physically and chemically stable and able of delivering either accurate doses and high fine particle fraction of low strength active ingredients by using a high- or medium resistance device.
REFERENCES:
patent: 6521260 (2003-02-01), Staniforth
patent: 6528096 (2003-03-01), Musa et al.
patent: 6645466 (2003-11-01), Keller et al.
patent: 20030133880 (2003-07-01), Musa et al.
patent: 2 347 856 (2000-05-01), None
patent: 0 239 798 (1987-10-01), None
patent: 0 441 740 (1991-08-01), None
patent: 0 606 486 (1994-07-01), None
patent: 1242211 (1971-08-01), None
patent: 1381872 (1975-01-01), None
patent: 1520247 (1978-08-01), None
patent: 1571629 (1980-07-01), None
patent: WO 8705213 (1987-09-01), None
patent: WO 9311746 (1993-06-01), None
patent: 95 11666 (1995-05-01), None
patent: WO 9524889 (1995-09-01), None
patent: WO 9602231 (1996-02-01), None
patent: 96 23485 (1996-08-01), None
patent: WO 9831351 (1998-07-01), None
patent: WO 9831353 (1998-07-01), None
patent: 00 28979 (2000-05-01), None
patent: WO 0033789 (2000-06-01), None
patent: WO 0053157 (2000-09-01), None
D. Ganderton,J. Pharm. Pharmac., vol. 21, pp. 9S-18S (1969).
K.S. Murthy et al,J. Pharmaceutical Sciences, vol. 66, pp. 1215-1219 (1977).
H.M. Mahmoud et al,Acta Pharm. Fenn., vol. 94, pp 125-131 (1985).
Z.T. Chowhan et al,J. Pharmaceutical Sciences, vol. 75, pp. 534-541 (1986).
H.V. van Kamp et al,Pharm. Acta Helv., vol. 61, pp. 22-29 (1986).
N.M. Kassem, Thesis, pp. 188-213 (1990).
Remington's Pharmaceutical Sciences, 18th Ed., A.R. Gennaro, Ed., Mack Publishing Co., Easton, PA, pp. 589, 593, 602, 1451, 1452, 1633, 1636, 1637 (1990).
D. Ganderton et al., Advances in Pharmaceutical Sciences, Academic Press, pp. 165-191 (1992).
J. Peart et al, Pharmaceutical Research, vol. 14, No. 11, Nov. 1997 (Supplement), 1997 AAPS Annual Meeting, Contributed Papers, Abstracts, Boston, MA, Nov. 2-6, 1997, Abstract No. 1405.
Hancock, et al., J. Pharm. Sci., vol. 86, pp. 1-12 (1997).
X. M. Zeng, et al., Int J. Pharmaceutics, vol. 176, pp. 99-110 (1998).
S. Malamataris, Powder Technol., vol. 28, pp. 35-42 (1981).
Lindberg, Acta Pharm., Suecica, pp. 207-214 (1972).
H. Lieberman, et al., Pharmaceutical Dosage Forms, Dekker, pp. 77-85 (1998).
H.A. Lieberman, et al., “Pharmaceutical Dosage Forms”, Marcel Dekker, Inc., pp. 77-85, 1981.
Brambilla Gaetano
Ferrarini Lorenzo
Gill Rajbir
Morton David Alexander Vodden
Musa Rossella
Chiesi Farmaceutici S.p.A.
Henley III Raymond J.
Oblon & Spivak, McClelland, Maier & Neustadt P.C.
LandOfFree
Pharmaceutical formulations for dry powder inhalers in the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical formulations for dry powder inhalers in the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical formulations for dry powder inhalers in the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3399371